Last reviewed · How we verify
Fluoxetine 20 MG
At a glance
| Generic name | Fluoxetine 20 MG |
|---|---|
| Also known as | Prozac Weekly, Sarafem, Prozac, Budesonide powder, Prozac 20 MG Oral Tablet, Generic PISA® |
| Sponsor | Wake Forest University Health Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression (PHASE1, PHASE2)
- TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children (PHASE4)
- Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities (PHASE4)
- Dapagliflozin in Depression (PHASE1, PHASE2)
- Improving Outcomes in Depression in Primary Care in a Low Resource Setting (PHASE3)
- Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM) (EARLY_PHASE1)
- The Staged Treatment in Early Psychosis Study (PHASE3)
- Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT) (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluoxetine 20 MG CI brief — competitive landscape report
- Fluoxetine 20 MG updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI